TrialPath
Recruiting

Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.

NCT06697301 · Eikon Therapeutics
In plain English

Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.

Official title
A Multicenter, Randomized, Double-Blind, Active Comparator-Controlled, Adaptive Phase 2/3 Study to Evaluate the Safety and Efficacy of EIK1001 and Pembrolizumab Versus Placebo and Pembrolizumab as First-Line Therapy in Participants With Advanced Melanoma (TeLuRide-006)
About this study
This is a Multicenter, Randomized, Double-Blind, Active Comparator-Controlled, Adaptive Phase 2/3 Study to Evaluate the Safety and Efficacy of EIK1001 and Pembrolizumab Versus Placebo and Pembrolizumab as First-Line Therapy in Participants with Advanced Melanoma. The study includes dose optimization and expansion parts.
Eligibility criteria
Inclusion Criteria: To be eligible for inclusion in this study, participants must: * Be ≥ 18 years of age on the day of signing of informed consent. * Have a life expectancy of at least 3 months. * Have histologically or cytologically confirmed Stage 3 (unresectable) or Stage 4 metastatic melanoma per AJCC 8th ed. and be eligible for standard therapy with pembrolizumab. * Have at least 1 lesion with measurable disease at Baseline by CT or MRI according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 by assessment of local site Investigator/radiologist. * Have known BRAF V600 mutation status or consent to BRAF V600 mutation testing per local institutional standards during the screening period * Have completed prior radiotherapy at least 2 weeks prior to study treatment administration. * Have an ECOG Performance Status of 0 to 1. * Have adequate organ and marrow function as defined by normal CBC, coagulation, serum chemistry and liver function tests on specimens collected within 10 days of treatment start. * Have a negative serum pregnancy test within 72 hours prior to receiving the first dose of study medication (applies to women of childbearing potential \[WOCBP\]). * Be willing to use either 2 adequate methods of contraception, 1 adequate method plus a hormonal method of contraception, or be willing to abstain from heterosexual activity throughout the study (Visit 1 to 120 days after the last dose of study therapy; applies to WOCBP who are not menopausal for \> 2 years, post-hysterectomy/oophorectomy, or surgically sterilized). * Agree to use an approved adequate contraceptive method throughout the study (Visit 1 to 120 days after the last dose of study therapy; applies to sexually active male participants with a partner who is WOCBP). * Be willing and able to provide written, informed consent for the study. Exclusion Criteria: A participant is excluded from the study if any of the following criteria apply: * Has melanoma of ocular origin. * Is currently enrolled in or has recently participated in a study of an IMP and received an IMP within 4 weeks or 5 half-lives (whichever is shorter) of administration of EIK1001 or placebo. * Prior to the 1St dose of EIK1001 or placebo, the prospective participant has received systemic therapy for advanced melanoma. * Note: prior adjuvant or neoadjuvant melanoma therapies (such as anti-PD-1 or anti CTLA 4 therapies or BRAF/MEK inhibitors) are permitted if all related AEs have either returned to Baseline or stabilized, with a minimum of 6 months between the last dose of prior therapy and documented disease progression. * Experienced a ≥ Grade 3 AE while receiving prior anti PD 1 therapy. * Has had major surgery (\< 3 weeks prior to the first dose). * Has received a live-virus vaccination within 30 days of the first dose of study treatment. * Has a known history of prior malignancy, unless the participant has undergone potentially curative therapy with no evidence of disease recurrence for 5 years. * Has known active CNS metastases and/or carcinomatous meningitis. Participants with previously treated brain metastases may participate if they are clinically stable for at least 4 weeks with no evidence of new or enlarging brain metastases. There must be no need for immunosuppressive doses of glucocorticoids for at least 2 weeks prior to study treatment administration. * There is a mean resting QTcF \> 470 ms on triplicate electrocardiograms. * There is active autoimmune disease that has required systemic treatment in the past 2 years. The following autoimmune conditions are permitted: Type 1 diabetes, hypothyroidism (on hormone replacement), or- vitiligo, psoriasis and alopecia as long as no systemic treatment is required. * There is either chronic treatment with systemic steroids, other immunosuppressive medication, or either of these has been administered within 14 days of start of study treatment. * Note: Participants with asthma that require intermittent use of bronchodilators, inhaled steroids, or local steroid injections are eligible. Steroid replacement for adrenal insufficiency is also permitted. * There is a history of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/ interstitial lung disease. * There are any active infections requiring therapy. * There is uncontrolled human immunodeficiency virus (HIV) infection. HIV-infected participants with well-controlled HIV may enroll. * There is a positive test result for hepatitis B virus (HBV) or HCV indicating presence of virus (it is expected that all participants will have been serologically tested for hepatitis B in advance of this study, with HBsAG, anti-HBc IgG, and anti-HBs as per ASCO 2020 Provisional Clinical Opinion \[PCO\] on universal Serologic testing for hepatitis B at the onset of anticancer therapy; screening should also include an anti-HCV test prior to start of cancer treatment: * There is a history or clinical evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study or interfere with the participant's participation for the full duration of the study * Known psychiatric or substance abuse disorder that would interfere with cooperation with study requirements. * There is a known history of regular illicit drug use and/or recent history (within the last year) of substance abuse (including alcohol). * Participant is pregnant, breastfeeding, or planning to conceive or father children within the projected duration of the study. * Participant is currently receiving medications known to be strong inhibitors or inducers of CYP3A4 and CYP1A2.
Study design
Enrollment target: 740 participants
Allocation: randomized
Masking: quadruple
Age groups: adult, older_adult
Timeline
Starts: 2025-05-22
Estimated completion: 2040-12
Last updated: 2026-10-06
Interventions
Drug: EIK1001Drug: Pembrolizumab (KEYTRUDA® )
Primary outcomes
  • • Progression Free Survival (PFS) (up to 5 years)
  • • Overall survival (OS) (up to 5 years)
  • • Objective Response (OR) (Dose Optimization Only) (up to 5 years)
Sponsor
Eikon Therapeutics · industry
With: Merck Sharp & Dohme LLC
Contacts & investigators
ContactKrishna Kaza, Director Clinical Study Management · contact · Kazak@eikontx.com · +1 (516) 675-6163
InvestigatorEtah Kurland · study_director, Eikon Therapeutics
InvestigatorMuaz Sadeia · study_director, Eikon Therapeutics
All locations (127)
Ironwood Cancer & Research CentersRecruiting
Chandler, Arizona, United States
Genesis Cancer and Blood InstituteRecruiting
Hot Springs, Arkansas, United States
Helios Clinical ResearchRecruiting
Los Angeles, California, United States
Providence Medical FoundationRecruiting
Santa Rosa, California, United States
UCHealth Memorial Hospital CentralRecruiting
Colorado Springs, Colorado, United States
Christiana CareRecruiting
Newark, Delaware, United States
Bioresearch PartnerRecruiting
Hialeah, Florida, United States
Florida Clinical Trials Group - TamaracRecruiting
Tamarac, Florida, United States
The Center for Cancer and Blood DisordersRecruiting
Bethesda, Maryland, United States
MidAmerica Cancer CareRecruiting
Kansas City, Missouri, United States
Washington University School of Medicine in St. LouisRecruiting
St Louis, Missouri, United States
Gabrail Cancer Center Research LLCRecruiting
Canton, Ohio, United States
University of Pittsburgh Medical Center(UPMC)-Hillman Cancer CenterRecruiting
Pittsburgh, Pennsylvania, United States
Patientcare Clinical ResearchRecruiting
Sugar Land, Texas, United States
Cancer Care WollongongRecruiting
Wollongong, New South Wales, Australia
Icon Cancer Centre ChermsideRecruiting
Chermside, Queensland, Australia
Southern Adelaide Local Health Network Incorporated Flinders Medical CentreRecruiting
Bedford Park, South Australia, Australia
Eastern HealthRecruiting
Box Hill, Victoria, Australia
Peninsula and South Eastern Haematology and Oncology GroupRecruiting
Frankston, Victoria, Australia
Universitätsklinikum GrazRecruiting
Graz, Styria, Austria
Universitair Ziekenhuis AntwerpenRecruiting
Edegem, Antwerpen, Belgium
Cliniques Universitaires Saint-LucRecruiting
Brussels, Brussels Capital, Belgium
Centre Hospitalier Universitaire Universite Catholique de Louvain - Site GodinneRecruiting
Yvoir, Namur, Belgium
Universitair Ziekenhuis Leuven - Campus GasthuisbergRecruiting
Leuven, Vlaams Brabant, Belgium
Algemeen Ziekenhuis Groeninge - Campus KennedylaanRecruiting
Kortrijk, West-Vlaanderen, Belgium
Vitaz Primary LocationRecruiting
Sint-Niklaas, Belgium
Sunnybrook Research Ins<tuteRecruiting
Toronto, Ontario, Canada
Masaryk Memorial Cancer InstituteRecruiting
Brno, Brno, Czechia
University Hospital Hradec KraloveRecruiting
Sokolov, Hradce Kralove, Czechia
Aarhus UniversitetshospitalSuspended
Aarhus, Central Jutland, Denmark
Aalborg University HospitalSuspended
Aalborg, Nord Jutland, Denmark
Oulu University HospitalRecruiting
Oulu, Oulu, Finland
Tampere University HospitalRecruiting
Tampere, Pirkanmaa, Finland
Helsinki University HospitalRecruiting
Helsinki, Uusimaa, Finland
Centre Hospitalier Lyon-SudRecruiting
Pierre-Bénite, Auvergne-Rhône-Alpes, France
A ParéRecruiting
Boulogne, Boulogne, France
Centre Hospitalier Universitaire Grenoble AlpesRecruiting
La Tronche, Isère, France
CHU LilleRecruiting
Lille, Lille Cedex, France
Hôpital La TimoneRecruiting
Marseille, Marseille, France
Centre Hospitalier Universitaire (CHU) NiceRecruiting
Nice, PACA, France
Hôpital Bichat AP-HP Université Paris CitéRecruiting
Paris, Paris, France
ICO Saint HerblainRecruiting
Saint-Herblain, Pays de la Loire Region, France
CHU RouenRecruiting
Rouen, Rouen, France
Hospital Saint AndreRecruiting
Bordeaux, France
Universitätsmedizin MannheimRecruiting
Mannheim, Baden-Wurttemberg, Germany
Universitaetsklinikum Tuebingen (UKT)Recruiting
Tübingen, Baden-Wurttemberg, Germany
Klinik für Dermatologie, Venerologie und AllergologieRecruiting
Würzburg, Bavaria, Germany
University Hospital ErlangenRecruiting
Erlangen, Erlangen, Germany
Universitätsklinik Hamburg EppendorfRecruiting
Martinsried, Free and Hanseatic City of Hamburg, Germany
Universität LeipzigRecruiting
Haus, Leipzig, Germany
Elbe Kliniken Stade-BuxtehudeRecruiting
Buxtehude, Lower Saxony, Germany
Johannes Wesling Klinikum MindenRecruiting
Minden, North Rhine-Westphalia, Germany
University of Mainz Medical CenterRecruiting
Mainz, RLP, Germany
Universitätsklinikum Schleswig-Holstein - Campus KielRecruiting
Kiel, Schleswig-Holstein, Germany
Universitätsklinikum Schleswig-Holstein - Campus LübeckRecruiting
Lübeck, Schleswig-Holstein, Germany
Charite Department of Dermatology, Venereology and AllergologyRecruiting
Berlin, State of Berlin, Germany
University Hospital Carl Gustav Carus DresdenRecruiting
Dresden, Germany
Helios Klinikum ErfurtRecruiting
Erfurt, Germany
SRH Wald-Klinikum Gera GmbHRecruiting
Gera, Germany
Fachklinik HornheideRecruiting
Münster, Germany
National Institute of OncologyRecruiting
Budapest, Budapest, Hungary
University of PécsRecruiting
Pécs, Hungary
Soroka medical centerRecruiting
Beersheba, Be'er Sheva, Israel
Rabin Medical CenterRecruiting
Petah Tikva, Petach Tikva, Israel
Ella Lemelbaum Institute for Immuno-Oncology and MelanomaRecruiting
Ramat Gan, Ramat Gan, Israel
Tel Aviv Medical CenterRecruiting
Tel Aviv, Tel Aviv, Israel
Ospedale Casa Sollievo Della SofferenzaRecruiting
San Giovanni Rotondo, Foggia, Italy
Azienda Ospedaliera Universitaria SS Antonio e Biagio e Cesare ArrigoRecruiting
Alessandria, Italy, Italy
Ospedale San Vincenzo TaorminaRecruiting
Messina, Italy, Italy
Fondazione IRCSS - Istituto Nazionale dei TumoriRecruiting
Milan, Italy, Italy
AOU Policlinico di ModenaRecruiting
Modena, Italy, Italy
Istituto Oncologico Veneto IRCCSRecruiting
Padova, Italy, Italy
Azienda Provinciale per I Servizi SanitariRecruiting
Trento, Italy, Italy
IRCCS Ospedale Policlinico San MarinoRecruiting
Genoa, Liguria, Italy
IRCCS Ospedale San RaffaeleRecruiting
Milan, Milano, Italy
Humanitas Gavazzeni BergamoRecruiting
Bergamo, Province of Bergamo, Italy
Clinica Oncologia Delle MarcheRecruiting
Ancona, The Marches, Italy
UOC Immunoterapia OncologicaRecruiting
Siena, Tuscany, Italy
Christchurch Public HospitalRecruiting
Christchurch, Christchurch, New Zealand
Auckland City HospitalRecruiting
Auckland, New Zealand, New Zealand
Nordland Hospital TrustRecruiting
Bodø, Bodø, Norway
Oslo University Hospital - The Norwegian Radium HospitalRecruiting
Oslo, Oslo, Norway
Drammen HospitalRecruiting
Drammen, Oslofjord, Norway
Uniwersyteckie Centrum KliniczneRecruiting
Gdansk, Gdańsk, Poland
Prezychodnia Lekarska KOMED Roman KaraszewskiRecruiting
Konin, Konin, Poland
Mazowiecki Szpital Wojewódzki, Siedlckie Centrum OnkologiiRecruiting
Siedlce, Siedlce, Poland
Maria Sklodowska-Curie Na;onal Research Ins;tute of Oncology, Gliwice BranchRecruiting
Gliwice, Silesian Voivodeship, Poland
Maria Sklodowska-Curie National Cancer Research InstituteRecruiting
Warsaw, Warsaw, Poland
IPO LisboaRecruiting
Lisbon, Lisbon District, Portugal
Hospital da Luz LisboaRecruiting
Lisbon, Lisbon District, Portugal
Military Medical Academy- Department of OncologyRecruiting
Belgrade, Belgrade, Serbia
Cancercare Port Elizabeth - Langenhoven Drive Oncology CentreRecruiting
Port Elizabeth, Eastern Cape, South Africa
University of Pretoria, Steve Biko Academic HospitalRecruiting
Pretoria, Gauteng, South Africa
The Medical Oncology Centre of RosebankRecruiting
Saxonwold, Gauteng, South Africa
Abraham OncologyRecruiting
Richards Bay, KwaZulu-Natal, South Africa
Curo OncologyRecruiting
Pretoria, Pretoria, South Africa
Cape Town Oncology TrialsRecruiting
Cape Town, Western Cape, South Africa
TASK EdenRecruiting
George, Western Cape, South Africa
Kyungpook National University Chilgok HospitalRecruiting
Daegu, South Korea
Seoul National University HospitalRecruiting
Seoul, South Korea
Hospital Clínico de Santiago de CompostelaRecruiting
Santiago de Compostela, A Coruña, Spain
H. Germans Trias I Pujol (ICO-Badalona)Recruiting
Badalona, Badalona, Spain
Hospital Universitari DexeusRecruiting
Barcelona, Barcelona, Spain
Vall d' Hebron Institute of OncologyRecruiting
Barcelona, Barcelona, Spain
Hospital Universitario Marques de ValdecillaRecruiting
Santander, Cantabria, Spain
San Pedro de Alcántara HospitalRecruiting
Cáceres, Cáceres, Spain
Hospital Universitario Lucus AugustiRecruiting
Lugo, Galicia, Spain
Institut Català d'Oncologia Girona (ICO Girona)Recruiting
Girona, Girona, Spain
GenesisCare Madrid - Hospital San Francisco de AsísRecruiting
Madrid, Madrid, Spain
Hospital General Universitario Gregorio MarañónRecruiting
Madrid, Madrid, Spain
HM CIOCCRecruiting
Madrid, Madrid, Spain
Hospital 12 de OctubreRecruiting
Usera, Madrid, Spain
Hospital Regional UniversitarioRecruiting
Málaga, Malaga, Spain
Hospital Clinico Universitario Virgen de la ArrixacaRecruiting
Murcia, Murcia, Spain
Hospital Universitario Virgen de la VictoriaRecruiting
Málaga, Málaga, Spain
Hospital Clinic BarcelonaRecruiting
Barcelona, Spain, Spain
IVO - Fundacion Instituto Valenciano de OncologiaRecruiting
Valencia, Valencia, Spain
INCLIVA Instituto de Investigación SanitariaRecruiting
Valencia, Valencia, Spain
University Hospital of JerezRecruiting
Cadiz, Spain
Gävle SjukhusRecruiting
Gävle, Gävleborg County, Sweden
Karolinska University HospitalRecruiting
Stockholm, Södermanland County, Sweden
Universitätsspital ZürichRecruiting
Zurich, Canton of Zurich, Switzerland
Kantonsspital GraubündenRecruiting
Chur, Chur, Switzerland
Belfast City Hospital, Belfast Health and Social Care TrustRecruiting
Belfast, Belfast, United Kingdom
Guy's and St Thomas' NHS Foundation TrustRecruiting
London, England, United Kingdom
Sarah Cannon Research Institute LondonRecruiting
London, England, United Kingdom
University Hospital SouthamptonRecruiting
Southampton, Hampshire, United Kingdom